

Application No. 09/391,606

2

Amendments to the Claims:

1. (Currently amended) An immunogenic composition, comprising:
 - a first plasmid vector comprising:
 - a first nucleotide sequence encoding a major outer membrane protein (MOMP) of a strain of *Chlamydia pneumoniae*, said first nucleotide sequence being selected from the group consisting of those having SEQ ID Nos: 12, 13, and [[or]] 14 or encoding a MOMP having an amino acid sequence selected from the group consisting of SEQ ID Nos: [[,]] 15 and 16, and
 - a first promoter sequence operatively coupled to said first nucleotide sequence for expression of said MOMP in a host;
 - a second plasmid vector comprising:
 - a second nucleotide sequence encoding a 76 kDa protein of a strain of *Chlamydia pneumoniae*, said second nucleotide sequence being selected from the group consisting of those having SEQ ID Nos: 1, 2, 3 and [[, or]] 4, and a second promoter sequence operatively coupled to said second nucleotide sequence for expression of said 76 kDa protein in a host; and

a pharmaceutically-acceptable carrier therefor.
2. (Cancelled)
3. (Withdrawn) The immunogenic composition of claim 1 wherein the first nucleotide sequence encodes a MOMP from *Chlamydia trachomatis*.
4. and 5. (Cancelled)
6. (Previously amended) The immunogenic composition of claim 1 wherein the first promoter is a cytomegalovirus promoter.
7. (Cancelled)

Application No. 09/391,606

3

8. (Withdrawn) The immunogenic composition of claim 1 wherein the second nucleotide sequence encodes a 76 kDa protein from *Chlamydia trachomatis*.

9. (Cancelled)

10. (Currently amended) The immunogenic composition of claim 1 wherein said second nucleotide sequence is encodes the 76 kDa protein gene sequence encoding a protein having a molecular size of about 35 kDa and having SEQ ID No: 7.

11. (Currently amended) The immunogenic composition of claim 1 wherein said second nucleotide sequence is encodes the 76 kDa protein gene sequence encoding a protein having a molecular size of about 60 kDa and having SEQ ID No: 8 or 9.

12. (Previously amended) The immunogenic composition of claim 1 wherein said second promoter is a cytomegalovirus promoter.

13. to 17. (Cancelled)

18. (Previously amended) The immunogenic composition of claim 1 wherein said first plasmid vector is pCAMOMP and said second plasmid vector is pCA76kDa.

19. (Currently amended) The immunogenic composition of claim 1 wherein said first and second vectors are present in amounts such that upon administration of the composition to the host, the individual protective effect of the first [[each]] vector is not adversely affected by the second vector and the protective effect of the second vector is not adversely affected by the first vector [[othre]].

20. (Original) The immunogenic composition of claim 1 wherein said first and second vectors are present in amounts such that an enhanced protective effect is achieved in comparison to the individual vectors alone.

21. (Cancelled)

Application No. 09/391,606

4

22. (Cancelled)

23. (Cancelled)